AstraZeneca Cooperation Included in Kazakhstan’s $1.3 Billion Alatau Agreements

On 3 November, Kazakhstan included cooperation with AstraZeneca and Crescent Meditours in its Alatau City investment agreements, covering medical infrastructure development, investment attraction and scientific exchange. The nine agreements have a combined investment potential of $1.3 billion, but no separate healthcare project value was disclosed. This creates opportunities for hospital operators, pharmaceutical suppliers, medical technology companies and healthcare investors; HPC can support healthcare partnerships and supplier introductions.

If you are interested to enquire further, please fill in the form below with your details and one of our consultants will contact you shortly.